CLINICAL CHRONOPHARMACOLOGY OF ORAL SUSTAINED-RELEASE ISOSORBIDE-5-MONONITRATE IN HEALTHY-SUBJECTS

被引:31
|
作者
LEMMER, B
SCHEIDEL, B
BLUME, H
BECKER, HJ
机构
[1] UNIV FRANKFURT,ZENTRUM PHARMAKOL,W-6000 FRANKFURT,GERMANY
[2] ZENT LAB DEUTSCH APOTHEKER,ESCHBORN,GERMANY
[3] STADTKRANKENHAUS HANAU,HANAU,GERMANY
关键词
ISOSORBIDE-5-MONONITRATE; SUSTAINED-RELEASE FORMULATION; PHARMACOKINETICS; CARDIOVASCULAR EFFECTS; CHRONOPHARMACOLOGY; HEALTHY VOLUNTEERS;
D O I
10.1007/BF00315142
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In 10 healthy male subjects the pharmacokinetics and haemodynamic effects of sustained-release isosorbide-5-mononitrate 60 mg (IS-5-MN) were studied after oral administration at two different times in the day (08.00 h and 20.00 h). Effects on blood pressure and heart rate after 3 min standing upright were measured in relation to the individual circadian control values. The pharmacokinetic parameters (C(max), t(max), AUC, t1/2) did not differ after morning and after evening dosing, t(max) being 5.2 h and 4.9 h, respectively. In contrast, the cardiovascular effects of IS-5-MN were clearly circadian phase-dependent. The maximum decrease in blood pressure decrease and increase in heart rate occurred significantly earlier after the evening (BPsys 2.8 h; BPdia 2.9 h; HR 3.8 h) than after the morning dose (BPsys 5.0 h; BPdia 6.0 h; HR 5.2 h). Thus, the peak haemodynamic effects coincided with the peak drug concentration after the morning dose, whereas the peak effect was in advance of the peak drug concentration after the evening dose of IS-5-MN. The data provide evidence of circadian phase-dependency in the dose-response relationship of oral IS-5-MN.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 28 条
  • [1] CHRONOPHARMACOLOGY OF ORAL NITRATES IN HEALTHY-SUBJECTS
    SCHEIDEL, B
    LEMMER, B
    CHRONOBIOLOGY INTERNATIONAL, 1991, 8 (05) : 409 - 419
  • [2] Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men
    Luo, WX
    Zhang, YD
    Shen, JP
    Ding, Y
    Huang, DK
    Luo, JP
    Qiu, J
    Jiang, ZH
    Peng, JH
    Sheng, LS
    ACTA PHARMACOLOGICA SINICA, 1999, 20 (10): : 951 - 956
  • [3] Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects
    Jin, Changyun
    Jeon, Ji-Young
    Im, Yong-Jin
    Jeong, Jin-A
    Kim, Yunjeong
    Chae, Soo-Wan
    Bentz, Juegen
    Kumke, Thomas
    Kim, Min-Gul
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (01) : 97 - 106
  • [4] Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate
    Sata, H
    Inoue, K
    Nii, T
    Kuroda, T
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 1997, 20 (10) : 1111 - 1115
  • [5] A COMBINED SINGLE AND MULTIPLE DOSE PHARMACOKINETIC STUDY OF ORAL ISOSORBIDE-5-MONONITRATE IN HEALTHY-VOLUNTEERS
    STORM, G
    OOSTERHUIS, B
    BRON, J
    WITTEBROOD, AJ
    DEJONG, AP
    JONKMAN, JHG
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1991, 12 (09) : 661 - 672
  • [6] PHARMACOKINETICS OF ORAL ISOSORBIDE-5-MONONITRATE IN PATIENTS WITH ISCHEMIC HEART-FAILURE
    MEISSNER, A
    PETERSENN, S
    HEIDEMANN, HT
    OSTERKAMP, U
    SIMON, R
    SCHULTE, HM
    KLINISCHE WOCHENSCHRIFT, 1991, 69 (05): : 213 - 219
  • [7] PLASMA PROFILE AND HEMODYNAMIC TOLERANCE TO ISOSORBIDE-5-MONONITRATE IN CONTROLLED-RELEASE FORM
    JAHNCHEN, E
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 : S15 - S17
  • [8] Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different prolonged release formulations
    Vree, TB
    Dammers, E
    Valducci, R
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2004, 42 (08) : 463 - 472
  • [9] Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab®)
    Stockis, A
    De Bruyn, S
    Deroubaix, X
    Jeanbaptiste, B
    Lebacq, E
    Nollevaux, F
    Poli, G
    Acerbi, D
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2002, 53 (01) : 49 - 56
  • [10] An Assessment of the Pharmacokinetics of a Sustained-release Formulation of a Tramadol/Acetaminophen Combination in Healthy Subjects
    Im, Yong-Jin
    Jeon, Ji-Young
    Kim, Eun-Young
    Kim, Yunjeong
    Oh, Dong-Joon
    Yoo, Ji-Seok
    Shin, Dae-Hee
    Chae, Soo-Wan
    Kim, Min-Gul
    CLINICAL THERAPEUTICS, 2015, 37 (02) : 376 - 389